Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Francesca Zacchi, Elena Castro, Kathleen Imbach, Alejo Rodriguez-Vida, Sara Simonetti, Begoña Mellado, Gisela Mir Arnau, Daniel Aguilar, Daniel Castellano, Miguel Angel Climent, Manuel J. Ramos, Angel Borque-Fernando, Jose Antonio Guerrero, Paula Gonzalez-Alonso, Jhudit Perez-Escuredo, Vanessa Izquierdo, Maria Isabel Saez, Heura Domenech, Sara Arce-Gallego, Bernardo Herrera-Imbroda, Jacques Planas, David Lorente, Albert Font, Anna Oliveira, Pablo Cresta Morgado, Victor Esquefa, Julian Brandariz, Nicolas Anselmino, Keyi Zhu, Patricia Troncoso, Monica Aguilera, Ana Vivancos, Paolo Nuciforo, Irene Casanova-Salas, Eduard Porta, Joan Carles, Amado J. Zurita, Joaquin Mateo

Open source

DOI: 10.1038/s41591-026-04671-5
Published: 2026-10-14
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04671-5,
  title = {Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial},
  author = {Francesca Zacchi and Elena Castro and Kathleen Imbach and Alejo Rodriguez-Vida and Sara Simonetti and Begoña Mellado and Gisela Mir Arnau and Daniel Aguilar and Daniel Castellano and Miguel Angel Climent and Manuel J. Ramos and Angel Borque-Fernando and Jose Antonio Guerrero and Paula Gonzalez-Alonso and Jhudit Perez-Escuredo and Vanessa Izquierdo and Maria Isabel Saez and Heura Domenech and Sara Arce-Gallego and Bernardo Herrera-Imbroda and Jacques Planas and David Lorente and Albert Font and Anna Oliveira and Pablo Cresta Morgado and Victor Esquefa and Julian Brandariz and Nicolas Anselmino and Keyi Zhu and Patricia Troncoso and Monica Aguilera and Ana Vivancos and Paolo Nuciforo and Irene Casanova-Salas and Eduard Porta and Joan Carles and Amado J. Zurita and Joaquin Mateo},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04671-5},
  url = {https://doi.org/10.1038/s41591-026-04671-5}
}

RIS

TY  - JOUR
TI  - Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
AU  - Francesca Zacchi
AU  - Elena Castro
AU  - Kathleen Imbach
AU  - Alejo Rodriguez-Vida
AU  - Sara Simonetti
AU  - Begoña Mellado
AU  - Gisela Mir Arnau
AU  - Daniel Aguilar
AU  - Daniel Castellano
AU  - Miguel Angel Climent
AU  - Manuel J. Ramos
AU  - Angel Borque-Fernando
AU  - Jose Antonio Guerrero
AU  - Paula Gonzalez-Alonso
AU  - Jhudit Perez-Escuredo
AU  - Vanessa Izquierdo
AU  - Maria Isabel Saez
AU  - Heura Domenech
AU  - Sara Arce-Gallego
AU  - Bernardo Herrera-Imbroda
AU  - Jacques Planas
AU  - David Lorente
AU  - Albert Font
AU  - Anna Oliveira
AU  - Pablo Cresta Morgado
AU  - Victor Esquefa
AU  - Julian Brandariz
AU  - Nicolas Anselmino
AU  - Keyi Zhu
AU  - Patricia Troncoso
AU  - Monica Aguilera
AU  - Ana Vivancos
AU  - Paolo Nuciforo
AU  - Irene Casanova-Salas
AU  - Eduard Porta
AU  - Joan Carles
AU  - Amado J. Zurita
AU  - Joaquin Mateo
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04671-5
UR  - https://doi.org/10.1038/s41591-026-04671-5
ER  -

APA

Zacchi, F., Castro, E., Imbach, K., Rodriguez-Vida, A., Simonetti, S., Mellado, B., Arnau, G. M., Aguilar, D., Castellano, D., Climent, M. A., Ramos, M. J., Borque-Fernando, A., Guerrero, J. A., Gonzalez-Alonso, P., Perez-Escuredo, J., Izquierdo, V., Saez, M. I., Domenech, H., Arce-Gallego, S., Herrera-Imbroda, B., Planas, J., Lorente, D., Font, A., Oliveira, A., Morgado, P. C., Esquefa, V., Brandariz, J., Anselmino, N., Zhu, K., Troncoso, P., Aguilera, M., Vivancos, A., Nuciforo, P., Casanova-Salas, I., Porta, E., Carles, J., Zurita, A. J., & Mateo, J. (2026). Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04671-5

Source records

crossref · retrieved 2026-11-04T10:57:26.097Z